FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2142625039> ?p ?o ?g. }

• W2142625039 endingPage "432" @default.
• W2142625039 startingPage "423" @default.
• W2142625039 abstract "Background: Low-dose cyclosporine therapy for severe plaque psoriasis is effective. Most side effects can be controlled by patient monitoring, with appropriate dose adjustment or pharmacologic intervention, or both, if indicated. Prevention or reversibility of laboratory and chemical abnormalities may be achieved by discontinuation of therapy after the induction of clearing. However, relapse occurs rapidly on discontinuation. Maintenance therapy with cyclosporine after induction has not been fully evaluated. Objective: Our purpose was to compare a regimen of 3.0 mg/kg per day of oral cyclosporine with placebo in maintaining remission or improvement in patients with psoriasis. Methods: After a 16-week unblinded induction phase in which 181 patients received cyclosporine, 5.0 mg/kg per day (an increase up to 6.0 mg/kg per day and a decrease to 3.0 mg/kg per day were allowed, if required, to achieve efficacy or tolerability, respectively), those patients showing a 70% decrease or more in involved body surface area (BSA) entered the 24-week maintenance phase and were randomly assigned to either placebo, cyclosporine, 1.5 mg/kg per day, or cyclosporine, 3.0 mg/kg per day. Patients were considered to have had a relapse when BSA returned to 50% or more of the prestudy baseline value. Clinical efficacy, adverse effects, and laboratory values were monitored regularly throughout both study phases. Results: During induction, cyclosporine at approximately 5.0 mg/kg per day produced a reduction in BSA of 70% or more in 86% of the patients. During maintenance, the median time to relapse was 6 weeks in both the placebo and cyclosporine 1.5 mg/kg per day groups, but was longer than the 24-week maintenance period in the 3.0 mg/kg per day group (p < 0.001 vs placebo). By the end of the maintenance period, 42% of the patients in the 3.0 mg/kg per day cyclosporine group had a relapse compared with 84% in the placebo group. Changes in laboratory values associated with the higher induction dosage generally exhibited partial or complete return toward mean prestudy baseline values during the maintenance phase, with the greatest degree of normalization in the placebo group. Conclusion: Cyclosporine, 3.0 mg/kg per day, adequately and safely maintained 58% of patients with psoriasis for a 6-month period after clearing of their psoriasis with doses of approximately 5.0 mg/kg per day. Low-dose cyclosporine therapy for severe plaque psoriasis is effective. Most side effects can be controlled by patient monitoring, with appropriate dose adjustment or pharmacologic intervention, or both, if indicated. Prevention or reversibility of laboratory and chemical abnormalities may be achieved by discontinuation of therapy after the induction of clearing. However, relapse occurs rapidly on discontinuation. Maintenance therapy with cyclosporine after induction has not been fully evaluated. Our purpose was to compare a regimen of 3.0 mg/kg per day of oral cyclosporine with placebo in maintaining remission or improvement in patients with psoriasis. After a 16-week unblinded induction phase in which 181 patients received cyclosporine, 5.0 mg/kg per day (an increase up to 6.0 mg/kg per day and a decrease to 3.0 mg/kg per day were allowed, if required, to achieve efficacy or tolerability, respectively), those patients showing a 70% decrease or more in involved body surface area (BSA) entered the 24-week maintenance phase and were randomly assigned to either placebo, cyclosporine, 1.5 mg/kg per day, or cyclosporine, 3.0 mg/kg per day. Patients were considered to have had a relapse when BSA returned to 50% or more of the prestudy baseline value. Clinical efficacy, adverse effects, and laboratory values were monitored regularly throughout both study phases. During induction, cyclosporine at approximately 5.0 mg/kg per day produced a reduction in BSA of 70% or more in 86% of the patients. During maintenance, the median time to relapse was 6 weeks in both the placebo and cyclosporine 1.5 mg/kg per day groups, but was longer than the 24-week maintenance period in the 3.0 mg/kg per day group (p < 0.001 vs placebo). By the end of the maintenance period, 42% of the patients in the 3.0 mg/kg per day cyclosporine group had a relapse compared with 84% in the placebo group. Changes in laboratory values associated with the higher induction dosage generally exhibited partial or complete return toward mean prestudy baseline values during the maintenance phase, with the greatest degree of normalization in the placebo group. Cyclosporine, 3.0 mg/kg per day, adequately and safely maintained 58% of patients with psoriasis for a 6-month period after clearing of their psoriasis with doses of approximately 5.0 mg/kg per day." @default.
• W2142625039 created "2016-06-24" @default.
• W2142625039 creator A5003620848 @default.
• W2142625039 creator A5004148649 @default.
• W2142625039 creator A5010660351 @default.
• W2142625039 creator A5016970292 @default.
• W2142625039 creator A5017402381 @default.
• W2142625039 creator A5027406924 @default.
• W2142625039 creator A5030517750 @default.
• W2142625039 creator A5030630461 @default.
• W2142625039 creator A5035093963 @default.
• W2142625039 creator A5038283366 @default.
• W2142625039 creator A5056200928 @default.
• W2142625039 creator A5057661348 @default.
• W2142625039 creator A5059278503 @default.
• W2142625039 creator A5066758718 @default.
• W2142625039 creator A5072890715 @default.
• W2142625039 creator A5076703794 @default.
• W2142625039 creator A5077091242 @default.
• W2142625039 creator A5077476041 @default.
• W2142625039 creator A5085853201 @default.
• W2142625039 creator A5086730068 @default.
• W2142625039 date "1997-03-01" @default.
• W2142625039 modified "2023-10-16" @default.
• W2142625039 title "Cyclosporine as maintenance therapy in patients with severe psoriasis" @default.
• W2142625039 cites W1968507200 @default.
• W2142625039 cites W1979198841 @default.
• W2142625039 cites W1995604182 @default.
• W2142625039 cites W2019276276 @default.
• W2142625039 cites W2038026816 @default.
• W2142625039 cites W2049933047 @default.
• W2142625039 cites W2066723587 @default.
• W2142625039 cites W2067327580 @default.
• W2142625039 cites W2081090975 @default.
• W2142625039 cites W2131493069 @default.
• W2142625039 cites W4246271143 @default.
• W2142625039 doi "https://doi.org/10.1016/s0190-9622(97)80219-8" @default.
• W2142625039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9091474" @default.
• W2142625039 hasPublicationYear "1997" @default.
• W2142625039 type Work @default.
• W2142625039 sameAs 2142625039 @default.
• W2142625039 citedByCount "94" @default.
• W2142625039 countsByYear W21426250392012 @default.
• W2142625039 countsByYear W21426250392013 @default.
• W2142625039 countsByYear W21426250392014 @default.
• W2142625039 countsByYear W21426250392015 @default.
• W2142625039 countsByYear W21426250392016 @default.
• W2142625039 countsByYear W21426250392017 @default.
• W2142625039 countsByYear W21426250392018 @default.
• W2142625039 countsByYear W21426250392019 @default.
• W2142625039 countsByYear W21426250392020 @default.
• W2142625039 countsByYear W21426250392021 @default.
• W2142625039 countsByYear W21426250392022 @default.
• W2142625039 countsByYear W21426250392023 @default.
• W2142625039 crossrefType "journal-article" @default.
• W2142625039 hasAuthorship W2142625039A5003620848 @default.
• W2142625039 hasAuthorship W2142625039A5004148649 @default.
• W2142625039 hasAuthorship W2142625039A5010660351 @default.
• W2142625039 hasAuthorship W2142625039A5016970292 @default.
• W2142625039 hasAuthorship W2142625039A5017402381 @default.
• W2142625039 hasAuthorship W2142625039A5027406924 @default.
• W2142625039 hasAuthorship W2142625039A5030517750 @default.
• W2142625039 hasAuthorship W2142625039A5030630461 @default.
• W2142625039 hasAuthorship W2142625039A5035093963 @default.
• W2142625039 hasAuthorship W2142625039A5038283366 @default.
• W2142625039 hasAuthorship W2142625039A5056200928 @default.
• W2142625039 hasAuthorship W2142625039A5057661348 @default.
• W2142625039 hasAuthorship W2142625039A5059278503 @default.
• W2142625039 hasAuthorship W2142625039A5066758718 @default.
• W2142625039 hasAuthorship W2142625039A5072890715 @default.
• W2142625039 hasAuthorship W2142625039A5076703794 @default.
• W2142625039 hasAuthorship W2142625039A5077091242 @default.
• W2142625039 hasAuthorship W2142625039A5077476041 @default.
• W2142625039 hasAuthorship W2142625039A5085853201 @default.
• W2142625039 hasAuthorship W2142625039A5086730068 @default.
• W2142625039 hasBestOaLocation W21426250391 @default.
• W2142625039 hasConcept C126322002 @default.
• W2142625039 hasConcept C141071460 @default.
• W2142625039 hasConcept C142724271 @default.
• W2142625039 hasConcept C16005928 @default.
• W2142625039 hasConcept C197934379 @default.
• W2142625039 hasConcept C204787440 @default.
• W2142625039 hasConcept C27081682 @default.
• W2142625039 hasConcept C2776694085 @default.
• W2142625039 hasConcept C2778283404 @default.
• W2142625039 hasConcept C2778375690 @default.
• W2142625039 hasConcept C2778715236 @default.
• W2142625039 hasConcept C2780564577 @default.
• W2142625039 hasConcept C2781413609 @default.
• W2142625039 hasConcept C27924281 @default.
• W2142625039 hasConcept C71924100 @default.
• W2142625039 hasConcept C90924648 @default.
• W2142625039 hasConceptScore W2142625039C126322002 @default.
• W2142625039 hasConceptScore W2142625039C141071460 @default.
• W2142625039 hasConceptScore W2142625039C142724271 @default.
• W2142625039 hasConceptScore W2142625039C16005928 @default.
• W2142625039 hasConceptScore W2142625039C197934379 @default.
• W2142625039 hasConceptScore W2142625039C204787440 @default.

• next